The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

I. Rini, Brian; Battle, Dena; A. Figlin, Robert; J. George, Daniel; J. Hammers, Hans; Hutson, Tom; Jonasch, Eric; W. Joseph, Richard; F. McDermott, David; J. Motzer, Robert; K. Pal, Sumanta; J. Pantuck, Allan; I. Quinn, David; Seery, Virginia; H. Voss, Martin; G. Wood, Christopher; S. Wood, Laura; B. Atkins, Michael

doi:10.1186/s40425-019-0813-8

Public

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

Published in Journal for ImmunoTherapy of Cancer • Dec 1, 2019

Authors:

Brian I. Rini

Dena Battle

Robert A. Figlin

Abstract

The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as mono...

View

Open Access

Subject

Medicine

Nivolumab

Ipilimumab

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!